Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)

The primary objective of this study is to demonstrate non-inferiority in pharmacokinetic (PK) parameters of subcutaneous (SC) vs intravenous (IV) tarlatamab administration and to characterize the efficacy, safety, and tolerability of SC tarlatamab in participants with relapsed extensive-stage small-cell lung cancer (ES-SCLC) after platinum-based chemotherapy.

Trial Details

NCT ID
NCT07778316
Phase
PHASE3
Sponsor
Amgen
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Tarlatamab
Locations (sample)
  • Orlando, Florida, United States|28.53834,-81.37924
  • Grand Rapids, Michigan, United States|42.96336,-85.66809
  • Omaha, Nebraska, United States|41.25626,-95.94043
  • Elizabeth Vale, South Australia, Australia|-34.74857,138.66819
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Participant has provided informed consent prior to initiation of any study specific activities/procedures.
  • Age ≥ 18 years (or legal adult age within country, whichever is older) at the time of signing the informed consent.
  • Histologically or cytologically confirmed SCLC with demonstrated progression or relapse.
  • Participants who progressed or recurred following 1 platinum-based regimen.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →